Rep. Lisa C. McClain Purchases Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Key Points

• Representative Lisa C. McClain purchased shares of Medpace Holdings, Inc. (NASDAQ: MEDP) valued between $1,001 and $15,000 on July 22nd.
• Medpace reported a net margin of 18.74%, with revenue of $603.31 million for the quarter, exceeding expectations by over $65 million.
• Insider trading included CFO Kevin M. Brady and CEO August J. Troendle, who sold a combined total of 60,487 shares, significantly reducing their positions in the company.

Representative Lisa C. McClain (R-Michigan) recently bought shares of Medpace Holdings, Inc. NASDAQ: MEDP. In a filing disclosed on August 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in Medpace stock on July 22nd. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Autoliv NYSE: ALV on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Arthur J. Gallagher & Co. NYSE: AJG on 8/4/2025.
• Sold $1,001 - $15,000 in shares of SAP NYSE: SAP on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of XPO NYSE: XPO on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Lithia Motors NYSE: LAD on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Sanofi NASDAQ: SNY on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Waters NYSE: WAT on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Group 1 Automotive NYSE: GPI on 7/22/2025.

Medpace Stock Performance

NASDAQ:MEDP traded down $0.77 on Tuesday, reaching $462.14. The company's stock had a trading volume of 277,284 shares, compared to its average volume of 455,060. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $501.30. The firm has a market cap of $12.98 billion, a PE ratio of 34.36, a PEG ratio of 2.88 and a beta of 1.42. The business's 50-day moving average price is $366.17 and its two-hundred day moving average price is $331.80.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The firm had revenue of $603.31 million during the quarter, compared to analysts' expectations of $537.70 million. During the same period in the previous year, the firm earned $2.75 earnings per share. The company's revenue was up 14.2% on a year-over-year basis. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, sell-side analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft boosted their target price on Medpace from $270.00 to $430.00 and gave the company a "hold" rating in a research note on Wednesday, July 23rd. Barclays upped their target price on Medpace from $300.00 to $450.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 23rd. Cowen lowered Medpace from a "buy" rating to a "sell" rating in a report on Wednesday, July 23rd. Truist Financial upped their target price on Medpace from $298.00 to $436.00 and gave the stock a "hold" rating in a report on Wednesday, July 23rd. Finally, William Blair reiterated a "market perform" rating on shares of Medpace in a report on Wednesday, July 23rd. Two research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, Medpace has a consensus rating of "Reduce" and an average price target of $406.60.

Hedge Funds Weigh In On Medpace

Institutional investors and hedge funds have recently made changes to their positions in the company. Geneos Wealth Management Inc. grew its position in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after purchasing an additional 37 shares during the last quarter. Brooklyn Investment Group grew its position in Medpace by 244.8% during the first quarter. Brooklyn Investment Group now owns 100 shares of the company's stock worth $30,000 after buying an additional 71 shares in the last quarter. Whittier Trust Co. grew its position in Medpace by 47.3% during the first quarter. Whittier Trust Co. now owns 109 shares of the company's stock worth $33,000 after buying an additional 35 shares in the last quarter. Employees Retirement System of Texas acquired a new stake in Medpace during the second quarter worth approximately $36,000. Finally, Colonial Trust Co SC grew its position in Medpace by 150.0% during the fourth quarter. Colonial Trust Co SC now owns 175 shares of the company's stock worth $58,000 after buying an additional 105 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Insider Buying and Selling at Medpace

In related news, CEO August J. Troendle sold 48,487 shares of the stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $451.69, for a total transaction of $21,901,093.03. Following the sale, the chief executive officer owned 962,615 shares of the company's stock, valued at $434,803,569.35. This represents a 4.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, General Counsel Stephen P. Ewald sold 3,000 shares of the stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $450.00, for a total value of $1,350,000.00. Following the sale, the general counsel directly owned 10,343 shares in the company, valued at $4,654,350. This represents a 22.48% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 112,788 shares of company stock valued at $51,018,354 over the last ninety days. 20.30% of the stock is owned by corporate insiders.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.